GlassScriptPhysician profile
Natalie A Stanton
NPI 1528230737
$5,871.32
in general payments reported to CMS, 2019-2025
60 companies · $666 in 2025
The $666 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $507 · 2021: $117 · 2022: $290 · 2023: $1,383 · 2024: $1,729 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,578.53 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $508.82 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Amgen INC. | $491.50 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $449.42 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $438.80 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $318.47 | 2023-2025 | Imbruvica, Darzalex, Erleada |
| Pfizer INC. | $302.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $230.67 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $185.96 | 2019-2025 | |
| Sobi, INC | $181.97 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.24 | 2019-2023 | |
| Genentech USA, INC. | $169.76 | 2023-2025 | Polivy, Lunsumio, Venclexta |
| Kite Pharma, INC. | $151.04 | 2020-2025 | Yescarta |
| Celgene Corporation | $127.17 | 2019-2024 | Reblozyl |
| Sirtex Medical INC | $121.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.00 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $111.00 | 2020-2024 | |
| Seagen INC. | $108.13 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Sumitomo Pharma America, INC. | $98.73 | 2023-2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.43 | 2019-2024 | Gilotrif |
| Daiichi Sankyo INC. | $90.56 | 2019-2024 | Enhertu |
| Rigel Pharmaceuticals, INC. | $81.21 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $71.94 | 2019-2024 | Libtayo |
| Gilead Sciences, INC. | $71.37 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $69.27 | 2023-2024 | Onivyde |
| Blueprint Medicines Corporation | $68.42 | 2020-2024 | Ayvakit |
| Pharmaessentia USA Corporation | $59.52 | 2023-2024 | Besremi |
| Tersera Therapeutics LLC | $55.71 | 2023-2024 | Zoladex |
| Aveo Pharmaceuticals, INC. | $52.12 | 2023-2024 | Fotivda |
| Beigene USA, INC. | $47.80 | 2024 | Brukinsa |
| Lilly USA, LLC | $46.42 | 2019-2024 | Verzenio, Jaypirca |
| Cti Biopharma Corp. | $45.48 | 2023 | Vonjo |
| Exelixis INC. | $40.30 | 2024-2025 | Cabometyx |
| Array Biopharma INC | $37.37 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Legend Biotech USA INC. | $35.52 | 2024 | |
| Myovant Sciences INC. | $34.82 | 2021 | |
| Astellas Pharma US INC | $34.13 | 2023-2024 | Xospata |
| Jazz Pharmaceuticals INC. | $32.56 | 2020-2023 | |
| Geron Corporation | $29.46 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $29.39 | 2023 | Xpovio |
| Sun Pharmaceutical Industries INC. | $28.86 | 2019-2023 | Odomzo, Yonsa |
| Genmab U.S., INC. | $28.49 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $27.35 | 2023 | Monoferric |
| Fresenius Kabi USA, LLC | $26.47 | 2024 | Stimufend |
| Spectrum Pharmaceuticals INC. | $25.51 | 2024 | Rolvedon |
| Mirati Therapeutics, INC. | $25.23 | 2023 | Krazati |
| Puma Biotechnology, INC. | $25.02 | 2023 | |
| Dendreon Pharmaceuticals LLC | $24.99 | 2024 | Provenge |
| Stemline Therapeutics INC. | $24.11 | 2024 | Orserdu |
| Eisai INC. | $23.32 | 2023 | |
| Amneal Pharmaceuticals LLC | $22.37 | 2024 | Avastin, Neupogen, Neulasta |
| Pharmacyclics LLC, An Abbvie Company | $21.34 | 2020 | |
| Agios Pharmaceuticals, INC. | $19.57 | 2024 | Pyrukynd |
| Clovis Oncology, INC. | $18.22 | 2019 | |
| Adaptive Biotechnologies Corporation | $18.03 | 2024 | Clonoseq |
| Springworks Therapeutics, INC. | $17.93 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $16.78 | 2023 | Qinlock |
| Dova Pharmaceuticals | $15.35 | 2019 | |
| Emd Serono, INC. | $14.66 | 2024 | |
| Abbvie INC. | $14.42 | 2019 | |
| Glaxosmithkline, LLC. | $13.60 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.